Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

Inclusion Criteria:

• Major patients with myeloproliferative neoplasms (polycythemia vera, essentialthrombocythaemia or myelofibrosis)
• and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon,ruxolitinib or bled for more than 6 months
• and suffering of persistent aquagenic pruritus
• and with a pruritus intensity on Analogic Visual Scale >5/10
• patients who gave their written consent for participation in the study

Exclusion Criteria:

• patients with a physical or psychological disability to sign the consent form
• patients with myeloproliferative neoplasms and suffering of aquagenic pruritus butonly treated by aspirin
• patients already included in another therapeutic protocol
• patients with diffuse dermatological disease where pruritus may be present (psoriasis,atopic dermatitis, prurigo
• patients already on anti-anxiety and / or anti-depressant treatment
• patients with absolute contraindications to the use of Aprepitant or Hydroxyzine
• hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients
• lactose intolerance
• pregnant or lactating women